Latest News
A new report from the BVCA applies two Public Market Equivalent (PME) methodologies to present a comparison of the relative performance of private capital funds managed by BVCA members against the UK public equity market, as represented by the FTSE All-Share Total Return index.
The findings are striking. The BVCA analysis shows that the private equity and venture capital funds in the dataset have collectively outperformed the public market as represented by the FTSE All-Share Total Return Index every year since 1991. The sole exception to this is 2006 when private equity and venture capital outperformed on one PME measure
BV Investment Partners (BV), a middle-market private equity firm focused on the tech-enabled business services, software and IT services sectors, has made a significant, growth-oriented investment in EMS Management & Consultants (EMS|MC), in partnership with the existing management team.
EMS|MC is the leading provider of revenue cycle management and technology solutions for the emergency medical services (EMS) industry.
EMS|MC, founded in 1996 and based in Winston-Salem, North Carolina, is one of the nation’s largest revenue cycle management providers focused exclusively on EMS, serving over 260 public, private, hospital-affiliated and non-profit EMS agencies across 24 states. The Company’s proprietary
Azora, a Madrid-based European private equity real estate manager, has completed the acquisition of Bluserena SPA, the second largest resort operator in Italy, from the Maresca family.
The acquisition has been completed on behalf of Azora’s latest pan-European hospitality fund, Azora European Hotel & Lodging, FCR (the fund).
Founded in 1985 by Carlo Maresca SPA, Bluserena manages a portfolio of 13 hotels, eight of which it owns. The hotels are spread across the main Italian tourist coastal destinations including Sardinia, Sicily, Apulia, Abruzzo, Piedmont and Calabria.
The portfolio totals over 4,200 keys and consists of eleven 4* category
Brazilian unicorn 2TM Group, the holding company for MercadoBitcoin.com, Latin America’s largest crypto exchange, has raised an additional USD50.3 million in a second closing of its Series B round.
US-based 10T and Tribe Capital, crypto & blockchain expert funds, Brazilian companies Traders Club, Pipo Capital and Endeavor also joined as new investors. This is 10T’s first investment in a Latin American company.
The current round had its first closing in July, when SoftBank invested USD200 million. This additional funding further solidifies 2TM’s position among other crypto-native unicorns worldwide.
Roberto Dagnoni, CEO, highlights 2TM’s drive to accelerate international expansion in Latin
Speedinvest, one of Europe’s leading early-stage investors with more than EUR600 million AUM, today announces the launch of a new EUR80 million Climate & Industry Opportunity fund.
The fund will primarily provide long-term support for Speedinvest’s existing sustainability-oriented startups, while also targeting selected non-portfolio startups that are accelerating European industry’s efforts to digitise and decarbonise.
The fund will conduct follow-on funding for Speedinvest’s existing and growing portfolio of sustainability-focused investments, including TWAICE, Planetly, Sylvera, Greyparrot, and One.Five. The new fund will back these innovative companies through co-investments in new rounds via Speedinvest’s existing pro-rata rights, allowing them to scale further
Global consultancy Berkeley Research Group (BRG) has released the results of its 2021 BRG M&A Disputes Report which featured quantitative and qualitative research providing an outlook on the global M&A disputes landscape.
As the M&A market remained extremely strong in 2021 and is expected to stay that way into next year, the data delivers insight into factors driving an increase in disputes. Those factors include innovative deal structures, new investment vehicles, advances in technology and rapidly changing economic conditions.
Following BRG’s inaugural effort from 2020 focused specifically on the Asia–Pacific (APAC) region, this year’s report offers a global outlook adding
Growth equity investor Gresham House Ventures has sold its stake in Vian Marketing, the holding company for stand-up paddleboard owner Tushingham Sails, best known for its Red Paddle Co brand.
Thought Machine, a cloud native core banking technology firm, has closed its series C funding round, bringing USD200 million into the business from new and existing investors. This new round sees Thought Machine achieve unicorn status.
This round was led by Nyca Partners, a New York and San Francisco-based venture capital firm, with investment also coming from the investment arms of some of Thought Machine’s global tier one banking clients – ING Ventures, JPMorgan Chase, and Standard Chartered Ventures. Existing investors Lloyds Banking Group, British Patient Capital, Eurazeo, SEB, Molten Ventures (formerly Draper Esprit), Backed, and IQ Capital have all
Raycast, a platform that provides developers with quick access to their tools, has raised USD15 million in a Series A funding round led by Accel and Coatue.
Also participating in the round were angel investors Johnny Boufarhat, CEO and founder of Hopin; Jeff Weinstein, Product at Stripe; Jason Warner, former CTO of GitHub and Ott Kaukver, CTO of Checkout.com and ex-CTO of Twilio, among others. The investment will be used to double down on building Raycast’s community of developers and tools, accelerate platform growth and, for the first time, bring Raycast to teams.
Raycast was founded in 2020 by
EverImmune, a biotechnology company specialising in the development of live biotherapeutic products in the field of microbiota oncology, today announces it has raised more than EUR5 million (approximately USD6 million) in a Series A funding from undisclosed private investors.
EverImmune was created in 2016 as a spinoff from Gustave Roussy; Europe’s first cancer institute, based near Paris, France. It harnesses the gut microbiota for the development of a unique theragnostic approach combining diagnostic and therapeutic technologies to restore the response to Immune Checkpoint Inhibitors (ICIs) in cancer patients.
The proceeds of this funding will support the clinical development of
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
